Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (9914)	1/3/2004 7:28:19 PM
From: Ian@SI	Read Replies (1) of 52153

Barron's takes a gentle shot at AZN... online.wsj.com MONDAY, JANUARY 5, 2004 Heartburn Hotel The purple-pill maker has been flying, but keep one eye on the questions about its new drugs By BILL ALPERT INVESTORS LIKE ASTRAZENECA, with good reason. Since emerging from the 1999 combination of Sweden's Astra and Britain's Zeneca, the company has tapped a pipeline of successful drugs -- such as Nexium, its widely advertised "purple pill" for heartburn. [snip]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next